ArticleScientific reports2026
Enhanced diagnostic tools for visceral leishmaniasis using kinase based antigens in Brazilian human and canine samples.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Visceral leishmaniasis (VL), caused by Leishmania infantum, is a major public health concern in Brazil, with domestic dogs as key reservoirs. Accurate diagnosis is crucial, but current tools like rK39 have limited sensitivity and regional variability. This study evaluated three recombinant kinase antigens-Repressor of Differentiation Kinase 2 (RDK2), Aurora I-related kinase (LdAIRK), and Activated C Kinase Receptor (LACK)derived from Leishmania donovani for their diagnostic potential in canine VL (CanL) and RDK2 in human VL. These antigens were selected based on amastigote-stage expression, conservation among virulent strains, and low homology with host proteins or co-endemic pathogens. Using computational prediction, and immunoproteomics, antigens were expressed and further validated via ELISA and dipstick assays. Serum samples from humans (VL, n = 40; controls, n = 19) and dogs (CanL, n = 36; controls, n = 36) were collected in Teresina, Brazil. RDK2 showed (90% sensitivity, 78.95% specificity) for human VL, while LdAIRK showed the highest diagnostic accuracy for CanL (88.89%, 97.22%), followed by LACK and RDK2. Dipstick tests confirmed these findings, offering rapid, field-friendly alternatives and demonstrating enhanced performance compared to two reference rK39 tests, pending broader comparative validation. LdAIRK emerged as a promising diagnostic marker for CanL, with the potential to enhance VL control in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.